Studies of the immune response in heparin-induced thrombocytopenia
- 14 May 2009
- journal article
- Published by American Society of Hematology in Blood
- Vol. 113 (20), 4963-4969
- https://doi.org/10.1182/blood-2008-10-186064
Abstract
Heparin-induced thrombocytopenia (HIT) is caused by platelet-activating antibodies that recognize PF4/heparin complexes. Uncertainties remain regarding HIT immunobiology, including the temporal relation of antibody formation to onset of thrombocytopenia, and whether immunoglobulin class switching occurs. Using serial plasma samples from 2 heparin thromboprophylaxis trials, we determined the time of onset, antibody levels, and immunoglobulin class distributions (IgG, IgA, IgM) for 12 patients with HIT and 36 patients who formed anti-PF4/heparin antibodies, but did not develop HIT (“seropositive non-HIT controls”). In patients with HIT, anti-PF4/heparin antibodies became detectable 4 days (median) after starting heparin; antibody detection preceded the platelet count decline by 2 days (median). Patients with HIT produced higher levels of IgG antibodies, but similar IgA and IgM levels, compared with seropositive non-HIT controls. Among all 48 seroconverting patients, the first day of a positive antibody test (median, day 6) did not differ among the immunoglobulin classes. Thus, the HIT immune response does not exhibit the classic paradigm of IgM class precedence/immunoglobulin class switching; rather, relatively rapid formation of IgG antibodies is observed, sometimes with concomitant IgA and IgM formation. Compared with seropositive non-HIT controls, HIT patients develop significantly higher anti-PF4/heparin IgG levels that are detectable before the onset of thrombocytopenia.This publication has 27 references indexed in Scilit:
- Duration of Humoral Immunity to Common Viral and Vaccine AntigensThe New England Journal of Medicine, 2007
- Platelet factor 4 is a negative autocrine in vivo regulator of megakaryopoiesis: clinical and therapeutic implicationsBlood, 2007
- Drug-Induced Immune-Mediated Thrombocytopenia — From Purpura to ThrombosisThe New England Journal of Medicine, 2007
- Heparin-Induced ThrombocytopeniaThe New England Journal of Medicine, 2006
- Evaluation of pretest clinical score (4 T's) for the diagnosis of heparin‐induced thrombocytopenia in two clinical settingsJournal of Thrombosis and Haemostasis, 2006
- Laboratory testing for the antibodies that cause heparin-induced thrombocytopenia: How much class do we need?Journal of Laboratory and Clinical Medicine, 2005
- Use of Heparin during Cardiopulmonary Bypass in Patients with a History of Heparin-Induced ThrombocytopeniaThe New England Journal of Medicine, 2000
- Extensions and Applications of Event ChartsThe American Statistician, 2000
- The epitope specificity of heparin‐induced thrombocytopeniaBritish Journal of Haematology, 1996
- Heparin-Induced Thrombocytopenia in Patients Treated with Low-Molecular-Weight Heparin or Unfractionated HeparinThe New England Journal of Medicine, 1995